GSA Capital Partners LLP Makes New Investment in AxoGen, Inc. $AXGN

GSA Capital Partners LLP purchased a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 17,441 shares of the medical equipment provider’s stock, valued at approximately $806,000.

A number of other hedge funds have also made changes to their positions in AXGN. MCF Advisors LLC acquired a new stake in AxoGen in the 4th quarter worth approximately $30,000. Aquatic Capital Management LLC grew its holdings in AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the last quarter. Arax Advisory Partners grew its holdings in AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of AxoGen in the fourth quarter valued at approximately $36,000. Finally, Kestra Advisory Services LLC bought a new position in shares of AxoGen in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AXGN. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Wells Fargo & Company lifted their price objective on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Citizens Jmp boosted their price objective on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Thursday, July 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $55.00 price target on shares of AxoGen in a research report on Wednesday, July 29th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, AxoGen has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Insider Activity

In other news, Director Amy Mcbride Wendell sold 13,353 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director owned 107,976 shares of the company’s stock, valued at approximately $5,228,197.92. This represents a 11.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the sale, the executive vice president directly owned 50,135 shares in the company, valued at $2,373,390.90. This represents a 57.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 95,003 shares of company stock worth $4,482,997. Corporate insiders own 2.44% of the company’s stock.

AxoGen Stock Performance

Shares of NASDAQ AXGN opened at $50.19 on Wednesday. The business has a fifty day simple moving average of $43.72 and a 200 day simple moving average of $38.69. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -73.81 and a beta of 1.11. AxoGen, Inc. has a one year low of $13.64 and a one year high of $50.66. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Sell-side analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.